BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Digirad Corporation (DRAD) Reports First Quarter Financial Results


5/6/2013 11:02:51 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

POWAY, CA--(Marketwired - May 06, 2013) - Digirad Corporation (NASDAQ: DRAD) today reported revenue of $11.5 million for the first quarter and an ending cash, cash equivalents and available-for-sale securities balance of $25.8 million.

At the end of February, the Company announced that following a lengthy strategic review, management and the board of directors had determined a new strategic direction for the Company. That initiative included:

  • A significant restructuring, primarily of the Diagnostic Imaging camera operation to reduce costs by $3 million to $4 million, on an annual basis.

  • A go-forward focus on maximizing and growing cash flow from its DIS services business. This strategy will include executing on financially disciplined acquisitions that align to and expand cash flow from the DIS operations. The diagnostic imaging business will emphasize a streamlined camera selling effort and efficiency in generating cash flow from the service and maintenance business associated with its installed base of cameras.

  • The aggressive return of cash to shareholders via an increased stock repurchase program, for which the Board ultimately increased the stock repurchase program from its existing $4 million program ($2 million availability) to a $12 million program ($10 million availability).

Digirad CEO Todd Clyde commented on the progress made, "Commercial and corporate activity in the first quarter was brisk as the management team implemented major steps in the restructuring of the business and executed on the organizational changes that will result in a leaner, focused operation. Key recent moves included significant cuts in senior management and other positions that will not be required in the new corporate direction, a decrease in the size of the board of directors, and the acceleration in assessment of acquisition targets that might complement the DIS footprint."

Clyde continued, "Though these changes involved tough decisions and near term financial charges, we have already begun to decrease our ongoing expense levels in most key categories, and we should see a more significant impact of those reductions by the third quarter, with continued decreases in expenses through the end of fiscal year 2013."

Digirad President Matt Molchan said, "Run rates in the DIS business remained relatively stable in the first quarter. The year-over-year revenue and gross margin comparison were principally impacted by some pricing pressures and a favorable one-time workers compensation insurance credit of approximately $200,000 reflected in the Q1 2012 gross margin results. During the period, we also completed the integration of the operations of the business we acquired at the end of 2012 and that business began to contribute to our results in Q1 2013."

Molchan continued, "Though we experienced some large restructuring charges during the quarter and anticipate more charges in the second quarter, by the middle of the year we anticipate we will have the majority of those expenses behind us. In addition, since we announced our new focus, we have identified a growing number of potential "tuck-in" acquisition targets to assess in key DIS regions. The team is focused on implementing all aspects of our new strategy, and I am pleased with the progress we have made thus far. We should start to see the effects of our restructuring in the second half of 2013 as those efforts start translating into improved income and cash flow."

First Quarter 2013 Summary

  • Total revenue for the first quarter of 2013 was $11.5 million, compared to $13.0 million for the same period in the prior year. DIS revenue for the first quarter of 2013 was $8.9 million, compared to $9.3 million for the same period of the prior year, which included some pricing pressures experience during the 2013 first quarter. Diagnostic Imaging revenue for the first quarter of 2013 was $2.6 million, compared to $3.7 million for the same period of the prior year, reflecting a disruption as the Company deployed its restructuring plan.

  • Gross profit for the first quarter of 2013 was $2.8 million, or 24 percent of revenue, compared to $3.7 million, or 28 percent of revenue in the prior year quarter.

  • Net loss for the first quarter of 2013 was $2.4 million, or $0.13 loss per share, compared to a net loss of $1.3 million, or $0.07 loss per share, in the same period of the prior year. Adjusted net loss for the 2013 first quarter, excluding the $1.0 million in expenses incurred for nonrecurring items related to restructuring activities, was $1.4 million or $0.07 loss per share on an adjusted basis.

  • Operating expenses for the first quarter of 2013 was $5.2 million, compared to $5.0 million in the same period in the prior year. Adjusted operating expenses for the first quarter of 2013 was $4.2 million, compared to the $5.0 million in the same period of the prior year, which reflects the beginning of the restructuring expense reductions since the February 28, 2013 restructuring announcement.

  • Cash, cash equivalents and available-for-sale securities totaled $25.8 million as of March 31, 2013. Cash, cash equivalents and available-for-sale securities totaled $27.2 million as of December 31, 2012.

Conference Call Information
A conference call is scheduled for 10:00 a.m. EDT today to discuss the results and management's outlook. The call may be accessed by dialing 877-941-1427 five minutes prior to the scheduled start time and referencing Digirad. A simultaneous webcast of the call may be accessed online from the Events & Presentations link on the Investor Relations page at www.digirad.com; an archived replay of the webcast will be available within 15 minutes of the end of the conference call.

Use of Non-GAAP Financial Measures by Digirad Corporation
This Digirad news release presents the non-GAAP financial measures "adjusted operating expenses", "adjusted operating loss" and "adjusted loss per share" and "adjusted segment loss". The most directly comparable measure for these non-GAAP financial measures are operating expenses, operating loss, loss per share and segment loss. The company has included below unaudited adjusted financial information for the quarter ended March 31, 2013 and 2012, which present the Company's results of operations after excluding restructuring charges.

A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding Digirad's financial condition and results of operations is included as Exhibit 99.2 to Digirad's report on Form 8-K filed with the Securities and Exchange Commission on May 6, 2013.

Forward-Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. These include statements regarding the Company's ability to deliver value to customers, the Company's ability to grow and generate positive cash flow, the ability to execute on restructuring activities, and ability to successfully execute acquisitions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made, including the risks associated with changes in business conditions, technology, customers' business conditions, reimbursement, radiopharmaceutical shortages, economic outlook, operational policy or structure, acceptance and use of Digirad's camera systems and services, reliability, recalls, analysis of potential impairment and restructuring charges, the conclusion of our audit and other risks detailed in Digirad's filings with the U.S. Securities and Exchange Commission, including the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other reports. Readers are cautioned to not place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Digirad undertakes no obligation to revise or update the forward-looking statements contained herein.

(Financial tables follow)

                                                                            
                            Digirad Corporation                             
                 Condensed Consolidated Statements of Loss                  
                                (Unaudited)                                 
                                                                            
                                                      Three Months Ended    
(in thousands, except per share data)                      March 31,        
                                                   ------------------------ 
                                                       2013         2012    
                                                   -----------  ----------- 
                                                                            
Revenues:                                                                   
  DIS                                              $     8,939  $     9,289 
  Diagnostic Imaging                                     2,607        3,680 
                                                   -----------  ----------- 
    Total revenues                                      11,546       12,969 
                                                                            
Cost of revenues:                                                           
  DIS                                                    6,825        6,976 
  Diagnostic Imaging                                     1,904        2,321 
                                                   -----------  ----------- 
    Total cost of revenues                               8,729        9,297 
                                                   -----------  ----------- 
                                                                            
Gross profit                                             2,817        3,672 
                                                                            
                                                                            
Operating expenses:                                                         
  Research and development                                 818          897 
  Marketing and sales                                    1,236        1,715 
  General and administrative                             2,102        2,265 
  Amortization of intangible assets                         66           77 
  Restructuring charges                                  1,004            - 
                                                   -----------  ----------- 
Total operating expenses                                 5,226        4,954 
                                                   -----------  ----------- 
                                                                            
Loss from operations                                    (2,409)      (1,282)
                                                                            
Other income (expense):                                                     
  Interest income                                           22           26 
  Other expense                                            (32)         (12)
                                                   -----------  ----------- 
Total other income (expense)                               (10)          14 
                                                   -----------  ----------- 
Net loss                                           $    (2,419) $    (1,268)
                                                   ===========  =========== 
                                                                            
Net loss per share: Basic and diluted              $     (0.13) $     (0.07)
                                                   ===========  =========== 
                                                                            
Shares used in per share computations:                                      
                                                                            
Weighted average shares outstanding: Basic and                              
 diluted                                                19,322       19,242 
                                                   ===========  =========== 
                                                                            
                                                                            
                                                                            
                            Digirad Corporation                             
                       Adjusted Financial Information                       
                                (Unaudited)                                 
                                                                            
                                                                            
(in thousands, except per share                                             
 data)                                 Three Months Ended March 31, 2013    
                                   ---------------------------------------- 
                                                 Nonrecurring               
                                       GAAP        Items (1)   Adjusted (2) 
                                   ------------  ------------  ------------ 
                                                                            
Revenues:                                                                   
  DIS                              $      8,939  $         --  $      8,939 
  Diagnostic Imaging                      2,607            --         2,607 
                                   ------------  ------------  ------------ 
    Total revenues                       11,546            --        11,546 
                                                                            
Cost of revenues:                                                           
  DIS                                     6,825            --         6,825 
  Diagnostic Imaging                      1,904            --         1,904 
                                   ------------  ------------  ------------ 
    Total cost of revenues                8,729            --         8,729 
                                   ------------  ------------  ------------ 
                                                                            
Gross profit                              2,817            --         2,817 
                                                                            
Operating expenses:                                                         
  Research and development                  818            --           818 
  Marketing and sales                     1,236            --         1,236 
  General and administrative              2,102            --         2,102 
  Amortization of intangible                                                
   assets                                    66            --            66 
  Restructuring charges                   1,004        (1,004)            - 
                                   ------------  ------------  ------------ 
Total operating expenses                  5,226        (1,004)        4,222 
                                   ------------  ------------  ------------ 
                                                                            
Loss from operations                     (2,409)        1,004        (1,405)
                                                                            
Other income (expense):                                                     
  Interest income                            22            --            22 
  Other expense                             (32)           --           (32)
                                   ------------  ------------  ------------ 
Total other income (expense)                (10)           --           (10)
                                   ------------  ------------  ------------ 
Net loss                           $     (2,419) $      1,004  $     (1,415)
                                   ============  ============  ============ 
                                                                            
Net loss per share: Basic and                                               
 diluted (3)                       $      (0.13) $       0.05  $      (0.07)
                                   ============  ============  ============ 
                                                                            
Shares used in per share                                                    
 computations:                                                              
                                                                            
Weighted average shares                                                     
 outstanding: Basic and diluted          19,322        19,322        19,322 
                                   ============  ============  ============ 
                                                                            
(1) Reflects nonrecurring charges primarily related to restructuring of the 
Diagnostic Imaging camera operating activities.                             
                                                                            
(2) Adjusted financial information reflects GAAP results adjusted on a non- 
GAAP basis to exclude nonrecurring items noted.                             
                                                                            
(3) Net loss per share calculations are performed separately for each       
component presented. Therefore, the sum of the per share components from the
table may not equal the per share amounts presented.                        
                                                                            
                                                                            
                                                                            
                            Digirad Corporation                             
                       Adjusted Financial Information                       
                                (Unaudited)                                 
                                                                            
                                                                            
(in thousands, except per share                                             
 data)                                 Three Months Ended March 31, 2012    
                                   ---------------------------------------- 
                                                 Nonrecurring               
                                       GAAP        Items (1)   Adjusted (2) 
                                   ------------  ------------  ------------ 
                                                                            
Revenues:                                                                   
  DIS                              $      9,289  $         --  $      9,289 
  Diagnostic Imaging                      3,680            --         3,680 
                                   ------------  ------------  ------------ 
    Total revenues                       12,969            --        12,969 
                                                                            
Cost of revenues:                                                           
  DIS                                     6,976            --         6,976 
  Diagnostic Imaging                      2,321            --         2,321 
                                   ------------  ------------  ------------ 
    Total cost of revenues                9,297            --         9,297 
                                   ------------  ------------  ------------ 
                                                                            
Gross profit                              3,672            --         3,672 
                                                                            
Operating expenses:                                                         
  Research and development                  897            --           897 
  Marketing and sales                     1,715            --         1,715 
  General and administrative              2,265            --         2,265 
  Amortization of intangible                                                
   assets                                    77            --            77 
                                   ------------  ------------  ------------ 
Total operating expenses                  4,954            --         4,954 
                                   ------------  ------------  ------------ 
                                                                            
Loss from operations                     (1,282)           --        (1,282)
                                                                            
Other income (expense):                                                     
  Interest income                            26            --            26 
  Other expense                             (12)           --           (12)
                                   ------------  ------------  ------------ 
Total other income (expense)                 14            --            14 
                                   ------------  ------------  ------------ 
Net loss                           $     (1,268) $         --  $     (1,268)
                                   ============  ============  ============ 
                                                                            
Net loss per share: Basic and                                               
 diluted                           $      (0.07) $         --  $      (0.07)
                                   ============  ============  ============ 
                                                                            
Shares used in per share                                                    
 computations:                                                              
                                                                            
Weighted average shares                                                     
 outstanding: Basic and diluted          19,242        19,242        19,242 
                                   ============  ============  ============ 
                                                                            
(1) There were no nonrecurring restructuring charges during the quarter     
ended March 31, 2012.                                                       
                                                                            
(2) Adjusted financial information reflects GAAP results adjusted on a non- 
GAAP basis to exclude nonrecurring items noted.                             
                                                                            
                                                                            
                                                                            
                            Digirad Corporation                             
                       Adjusted Financial Information                       
                                (Unaudited)                                 
                                                                            
                                       Three Months Ended March 31, 2013    
                                   ---------------------------------------- 
                                                 Nonrecurring               
(in thousands)                         GAAP        Items (1)   Adjusted (2) 
                                   ------------  ------------  ------------ 
                                                                            
DIS                                                                         
Revenue                            $      8,939  $         --  $      8,939 
Gross Profit                              2,114            --         2,114 
Operating loss                             (144)           --          (144)
                                                                            
Diagnostic Imaging                                                          
Revenue                            $      2,607  $         --  $      2,607 
Gross Profit                                703            --           703 
Operating loss                           (2,265)        1,004        (1,261)
                                                                            
                                                                            
                                                                            
                                       Three Months Ended March 31, 2012    
                                   ---------------------------------------- 
                                                 Nonrecurring               
(in thousands)                         GAAP        Items (3)   Adjusted (2) 
                                   ------------  ------------  ------------ 
                                                                            
DIS                                                                         
Revenue                            $      9,289  $         --  $      9,289 
Gross Profit                              2,313            --         2,313 
Operating loss                             (168)           --          (168)
                                                                            
Diagnostic Imaging                                                          
Revenue                            $      3,680  $         --  $      3,680 
Gross Profit                              1,359            --         1,359 
Operating loss                           (1,114)           --        (1,114)
                                                                            
(1) Reflects nonrecurring charges related to restructuring of the Diagnostic
Imaging segment.                                                            
                                                                            
(2) Adjusted financial information reflects GAAP results adjusted on a non- 
GAAP basis to exclude nonrecurring items noted.                             
                                                                            
(3) There were no nonrecurring restructuring charges during the quarter     
ended March 31, 2012.                                                       
                                                                            
                                                                            
                                                                            

Investor Contact:
Matt Clawson
Allen & Caron
949-474-4300
Email Contact

Company Contact:
Jeffry Keyes
CFO
858-726-1600
Email Contact



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES